Latest Breaking News On - Lifesci partners - Page 5 : comparemela.com

Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022

Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalNawal ouzrenJeff goodenbourInstitut pasteurMary jane elliott jessica hodgsonCatherine leveauInternational media relationsConsilium strategic communicationsLifesci partnersAnnual genetic medicines symposiumCisplatin induced ototoxicityCochlear limitedInvestor relations

Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

23.06.2022 - REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will participate at the LifeSci Partners . Seite 1

Ronald martellCompany investor eventsJasper therapeutics incLifesci partnersAnnual genetic medicines symposiumChief executive officerJeet mahalChief operatingFinancial officerSenior vice presidentTranslational medicineInvestor events

Aerie Pharmaceuticals (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call Transcript

Aerie Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AERI) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive.

United statesSerge belangerOren livnatRaj kannanStacy kuGary sternbergJeff calabreseHans vitzthumCasey kopczynskiJason gerberryBausch lombLouise chenAnnabel samimyPeter langCarly kenselaarYigal nochomovitz

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer - read this article along with other careers information, tips and advice on BioSpace

Ashleyr robinsonKathleen mooreLaura benjaminUniversity of oklahomaLifesci partnersDrug administrationOncxerna therapeutics incXerna therapeuticsNavicixizumab plus paclitaxelPatients with platinum resistant ovarianPrimary peritonealFallopian tube cancerClinical oncologyChief executive officerOncxerna therapeuticsFast track

NLS Pharmaceutics AG: NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives

ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

United statesAlex zwyerKostenloser wertpapierhandelCindy rizzoPascal nigenExchange commissionAlpha bronzeWorld sleep congressEarly access programPharmaceutics ltdLifesci partnersChief executive officerSci partnersMazindol controlled releaseOrphan drug designations